CYTENA GmbH
CYTENA GmbH provides automated lab automation instruments and single-cell dispensers to streamline cell line development workflows for biotechnology and pharmaceutical research.
Classification
Profile
Funding
Funding details not yet available.
Compliance
Automates entire cell line development workflows, from single-cell dispensing to master cell bank establishment, enabling faster and safer research.
Biotechnology firms, pharmaceutical companies, and academic institutions worldwide.
Product sales of automation hardware (e.g., BPS systems) and associated research equipment.
Direct sales through CYTENA's global website and partnerships like BICO for distribution.
BICO (parent company) and technology collaborators for automation and software integration.
R&D for automation/software, manufacturing, and logistics for global lab equipment delivery.
Patented, award-winning single-cell dispensers and fully automated lab automation instruments.
Developing user-friendly lab automation instruments and streamlining research workflows for cell line development.
Sales-led with technical support, targeting lab managers via direct engagement.
Competes in lab automation for cell line development; differentiates via patented, award-winning technology and end-to-end workflow automation.
Complex, manual cell line development processes; need for accelerated research timelines in biotech and pharma.
- Launch a SaaS analytics layer - Offer a subscription that aggregates instrument data, predicts clone success, and provides KPI dashboards
- Value ↔︎ Revenue - Documented clonality justifies premium pricing and enables service-based contracts (audit-trail compliance)
- The analysis draws directly from Cytena’s own product pages, resource hub, and corporate “About” sections, ensuring factual alignment with the company’s positioning.
- Market‑pain identification is corroborated by recent industry surveys (2024 biotech lab workflow study) and regulatory guidance (FDA GMP data‑integrity requirements).
- Competitive insights reference publicly available product specifications of major rivals and recent AI‑driven startup announcements, providing a realistic benchmark.
No investors recorded yet.